Eligo Bioscience Raises €2M in Series A Funding

▤ Summary

Eligo Bioscience, a Paris, France-based antibiotics maker, raised €2m in Series A funding.In conjunction with the funding, Sebastien Groyer, Partner at Seventure, joined Eligo Bioscience’s board.Led by Xavier Duportet, CEO, Eligo Bioscience is based at Institut Pasteur in Paris.The company uses propietary technology to design new antibiotics, called Eligobiotics, that target harmful bacteria while sparing beneficial ones.In this way, they attack harmful or even resistant bacteria in a targeted way, whilst leveraging good microbiota within a patient.

▦ Linked Companies